Research programme: Neuroprotectin D1 - Anida Pharma

Drug Profile

Research programme: Neuroprotectin D1 - Anida Pharma

Alternative Names: NPD1 - Anida Pharma; Protectin D1

Latest Information Update: 03 Oct 2013

Price : $50

At a glance

  • Originator Anida Pharma
  • Developer ALS Therapy Development Institute; Anida Pharma
  • Class Docosahexaenoic acids; Small molecules
  • Mechanism of Action Apoptosis inhibitors; MTOR protein modulators; Proto oncogene protein c akt modulators; Proto-oncogene protein c-bcl-2 modulators; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Hearing loss; Parkinson's disease

Most Recent Events

  • 30 Sep 2013 The Michael J. Fox Foundation grants research grant to Anida Pharma for Parkinson's disease
  • 30 Sep 2013 Preclinical trials in Hearing loss in USA (Topical)
  • 30 Sep 2013 Preclinical trials in Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top